New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
10:00 EDTVTR, MGM, SPN, MFC, JOY, DOV, HEK, RDC, LUV, LSTR, FTI, PH, TKC, MKSI, KKR, CELGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Celgene (CELG) upgraded to Outperform from Sector Perform at RBC Capital... Celgene (CELG) upgraded to Overweight from Neutral at Piper Jaffray... Dover (DOV) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Buy from Neutral at Sterne Agee... Joy Global (JOY) upgraded to Overweight from Neutral at Piper Jaffray... KKR & Co. (KKR) upgraded to Buy from Neutral at Goldman... Landstar System (LSTR) upgraded to Outperform from Market Perform at Wells Fargo... MKS Instruments (MKSI) upgraded to Buy from Neutral at BofA/Merrill... Manulife Financial (MFC) upgraded to Buy from Neutral at BofA/Merrill... Southwest (LUV) upgraded to Buy from Hold at Deutsche Bank... Superior Energy (SPN) upgraded to Outperform from Sector Perform at RBC Capital... Turkcell (TKC) upgraded to Overweight from Neutral at HSBC... Rowan Companies (RDC) upgraded to Neutral from Underweight at JPMorgan... MGM Resorts (MGM) upgraded to Outperform from Neutral at Credit Suisse... Parker-Hannifin (PH)upgraded to Overweight from Neutral at JPMorgan... Ventas (VTR) upgraded to Buy from Hold at Jefferies... Heckmann (HEK) upgraded to Neutral from Sell at Ladenburg.
News For DOV;CELG;FTI;JOY;KKR;LSTR;MFC;MKSI;LUV;SPN;TKC;RDC;MGM;PH;HEK;VTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 9, 2014
08:28 EDTCELGCelgene price target raised to $130 from $112 at UBS
Subscribe for More Information
07:44 EDTCELGAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:18 EDTMKSIMKS Instruments price target raised to $43 from $37 at Stifel
Subscribe for More Information
06:40 EDTTKCTurkcell downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
06:19 EDTDOVDover downgraded to Sell from Hold at Deutsche Bank
Subscribe for More Information
05:46 EDTCELGCelgene presents POMALYST/IMNOVID Phase IIIb study results at ASH meeting
Celgene announced that results from the STRATUS trial, a single-arm phase IIIb study of pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society of Hematology annual meeting. Pomalidomide is marketed as POMALYST in the United States and IMNOVID in the European Union. In the study, 599 patients with refractory, or relapsed and refractory, disease who had previously failed lenalidomide and bortezomib had been enrolled at the time of the data cutoff. The primary endpoint was safety, and key secondary endpoints included pomalidomide exposure, overall response rate, or ORR, duration of response, or DOR, progression-free survival, or PFS, overall survival, or OS, and cytogenetic analyses. Patients had a median five prior therapies. All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent. At a median follow-up of 6.8 months with a median four cycles received, the median PFS and OS were 4.2 months and 11.9 months, respectively. The ORR was 35%, with 8% of patients achieving at least a very good partial response, or VGPR. The median DOR was 6.8 months. In patients refractory to prior lenalidomide or lenalidomide and bortezomib, similar PFS, OS, and ORR were achieved.
05:22 EDTCELGCelgene reports REVLIMID study data suggests improved response rates, PFS, OS
Subscribe for More Information
05:17 EDTCELGCelgene reports Vidaza Phase III study shows doubled overall survival times
Subscribe for More Information
December 8, 2014
14:06 EDTCELGCelgene reports luspatercept, sotatercept increased hemoglobin levels in trials
Subscribe for More Information
13:54 EDTCELGCelgene announces results from phase lll Revlimid study
Subscribe for More Information
10:00 EDTLUVOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
08:49 EDTDOVDover cuts FY14 adjusted EPS $4.55-$4.62 from $4.750$4.80, consensus $4.77
Subscribe for More Information
08:48 EDTDOVDover sees FY15 EPS $5.05-$5.30, consensus $5.21
Subscribe for More Information
08:47 EDTLUVSouthwest reports November 8.6B revenue passenger miles
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
06:27 EDTLUVSouthwest upgraded at Goldman
As previously reported, Goldman upgraded Southwest to Buy from Neutral. The firm believes shares can continue to move higher on the strong operating environment and improving net margins. Price target raised to $55 from $44.
06:08 EDTDOVDover to host investor meeting
Subscribe for More Information
05:44 EDTLUVSouthwest upgraded to Buy from Neutral at Goldman
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use